Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT: biomarkers of response to galcanezumab in high-frequency episodic migraine
2021-006176-16Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of galcanezumab in migraine and high-frequency episodic migraine (HFEM), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Functional brain alterations after 3 months of galcanezumab. Started Apr 2022; status: completed.
02
Drugs
galcanezumab
03
Conditions
migrainehigh-frequency episodic migraine (HFEM)
Beyond the preview
Go deeper on 2021-006176-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006176-16.